A Randomized, Placebo-Controlled, Double-Blind Six Month Study Followed by an Open-Label Extension Phase to Evaluate the Efficacy, Safety and Tolerability of MN-001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Phase of Trial: Phase II
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Tipelukast (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Sponsors MediciNova
- 10 Aug 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 10 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
- 01 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.